Outcome of directed share issue to sellers of Respiratory Motion

Press release: Uppsala, February 27, 2025

The Board of Directors of Senzime AB (publ) (”Senzime”) has, based on the authorization to issue shares granted by the general meeting on May 16, 2024 and as previously announced through a press release, resolved on February 26, 2025 on a directed issue of shares to sellers of Respiratory Motion, Inc. The directed share issue has been fully subscribed and in accordance with the Board of Directors’ resolution, 40,523 shares were subscribed and allocated during the subscription period.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: [email protected]

About Senzime

Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime’s TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime’s products are commercialized in over 30 countries including direct sales teams in US and Germany.

Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at senzime.com.

Downloads
Contact

Philip Siberg, CEO of Senzime

+46 (0) 70 790 6734
[email protected]
 

Subscribe

Click here to sign up to our latest news.

Subscription service
en sv de